DALLAS, July 12, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc. (Nasdaq:CPRX). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/CPRX
CPRX is trading above its upper Bollinger Band. Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.
Catalyst Pharmaceutical Partners Inc. (CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2009, the Company had two products in development. As of December 31, 2009, the Company was evaluating its product candidate, CPP-109 (its version of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. As of December 31, 2009, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. CPP-115, like vigabatrin (CPP-109), is a GABA-AT inhibitor. It is developed for both epilepsy (specifically, complex partial seizures and West Syndrome) and drug addiction (cocaine addition).
Message Board Search for CPRX: http://www.boardcentral.com/boards/CPRX
In the report, the analyst notes:
"CPRX recently announced its financial results for the three-month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per basic and diluted share, for the same period in 2009.
"CPRX recently announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management."
To read the entire report, visit: http://www.microstockprofit.com/lp/CPRX
See what investors are saying about CPRX at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.